AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges. Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership.
In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus. The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden. This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.
The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.
AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge.